Phase 3
Development Phase
2
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
0 competitors in Neoplasms, Rectal
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Jemperli
Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability‑high (MSI‑H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen.
View on EMADental Caries
Hepatitis B
Pulmonary Disease, Chronic Obstructive
Acute Coronary Syndrome
Infections, Meningococcal